{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:02:54Z","timestamp":1791874974366,"version":"4.3.4"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,1,7]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide over 3 years from patients with moderate-to-severe SLE. We report real-world patterns of medication use in patients enrolled in SPOCS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected at study entry; patients were followed twice annually according to local practice. Disease activity (SLE Disease Activity Index 2000 (SLEDAI-2K)), average oral glucocorticoid dose and use of other treatments\u2014specifically antimalarials, biologics and immunosuppressants\u2014were measured over time. Subgroup analyses were stratified by baseline interferon gene signature (IFNGS) status and disease activity (SLEDAI-2K) status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patient demographics and baseline characteristics were similar among subgroups; the majority of patients were on antimalarials (n=670; 81.1%), followed by glucocorticoids (n=537; 65.0%), immunosuppressants (n=453; 54.8%) and biologics (n=175; 21.2%). In the overall population, median (IQR) SLEDAI-2K scores decreased within 12 months (baseline: 8.0 (6.0\u201312.0); 12 months: 4.0 (2.0\u20138.0)) and remained stable thereafter. The mean (SD) daily oral glucocorticoid dose increased by 6 months (baseline: 6.0 (7.09); 6 months: 9.8 (8.67)) and remained stable thereafter. The proportion of patients who were on glucocorticoid doses &gt;5\u2009mg\/day ranged from ~20% to 33% throughout the study. In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03189875\">NCT03189875<\/jats:ext-link>; 16 June 2017.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001336","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:17Z","timestamp":1737676817000},"page":"e001336","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03189875","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03189875","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03189875","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"first","affiliation":[{"name":"Internal Medicine III, TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Peschken","sequence":"additional","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-7383","authenticated-orcid":false,"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Desta","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Hedberg","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Gr\u00fcnfeld E\u00e9n","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"AstraZeneca PLC, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Kielar","sequence":"additional","affiliation":[{"name":"AstraZeneca PLC, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chen","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca US, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-4563","authenticated-orcid":false,"given":"Bo","family":"Ding","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2025091513550053000_12.1.e001336.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.007"},{"key":"2025091513550053000_12.1.e001336.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39"},{"key":"2025091513550053000_12.1.e001336.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-017-0200-5","article-title":"Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)","volume":"18","author":"Chaigne","year":"2017","journal-title":"BMC Immunol"},{"key":"2025091513550053000_12.1.e001336.4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acr.20648","article-title":"Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort","volume":"64","author":"Urowitz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091513550053000_12.1.e001336.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091513550053000_12.1.e001336.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025091513550053000_12.1.e001336.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker410"},{"key":"2025091513550053000_12.1.e001336.8","first-page":"1006","article-title":"Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel","volume":"23","author":"Petri","year":"2014","journal-title":"Lupus (Los Angel)"},{"key":"2025091513550053000_12.1.e001336.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014460"},{"key":"2025091513550053000_12.1.e001336.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210882"},{"key":"2025091513550053000_12.1.e001336.11","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.85930"},{"key":"2025091513550053000_12.1.e001336.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2025091513550053000_12.1.e001336.13","first-page":"308","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus (Los Angel)"},{"key":"2025091513550053000_12.1.e001336.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250407"},{"key":"2025091513550053000_12.1.e001336.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907053010102"},{"key":"2025091513550053000_12.1.e001336.16","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti-IFN-\u03b1 monoclonal antibody trials in systemic lupus erythematosus","volume":"2009","author":"Yao","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"2025091513550053000_12.1.e001336.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"2025091513550053000_12.1.e001336.18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025091513550053000_12.1.e001336.19","unstructured":"AstraZeneca . Saphnelo (anifrolumab-fnia) prescribing information. 2022."},{"key":"2025091513550053000_12.1.e001336.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036563","article-title":"Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature","volume":"10","author":"Hammond","year":"2020","journal-title":"BMJ Open"},{"key":"2025091513550053000_12.1.e001336.21","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001032","article-title":"Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature","volume":"10","author":"Arnaud","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2025091513550053000_12.1.e001336.22","first-page":"664","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus (Los Angel)"},{"key":"2025091513550053000_12.1.e001336.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.22044"},{"key":"2025091513550053000_12.1.e001336.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"2025091513550053000_12.1.e001336.25","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.40086","article-title":"The biomarkers of lupus disease study: a bold approach may mitigate interference of background immunosuppressants in clinical trials","volume":"69","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091513550053000_12.1.e001336.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326"},{"key":"2025091513550053000_12.1.e001336.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02414-0","article-title":"The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus","volume":"23","author":"Mai","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025091513550053000_12.1.e001336.28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137132","article-title":"Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence","volume":"22","author":"Calzetta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025091513550053000_12.1.e001336.29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-017-0518-z","article-title":"Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials","volume":"37","author":"Sciascia","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2025091513550053000_12.1.e001336.30","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.4.279"},{"key":"2025091513550053000_12.1.e001336.31","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091513550053000_12.1.e001336.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091513550053000_12.1.e001336.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1451-5","article-title":"Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus","volume":"19","author":"Piga","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025091513550053000_12.1.e001336.34","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/acr.24740","article-title":"Patterns of medication use in systemic lupus erythematosus: a multicenter cohort study","volume":"74","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091513550053000_12.1.e001336.35","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091513550053000_12.1.e001336.36","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s12325-022-02148-8","article-title":"Treatment patterns and clinical characteristics of patients with systemic lupus erythematosus and musculoskeletal symptoms: a retrospective, observational study","volume":"39","author":"Bello","year":"2022","journal-title":"Adv Ther"},{"key":"2025091513550053000_12.1.e001336.37","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000480"},{"key":"2025091513550053000_12.1.e001336.38","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328363eba3"},{"key":"2025091513550053000_12.1.e001336.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201017"},{"key":"2025091513550053000_12.1.e001336.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09389-5","article-title":"Learning from the COVID-19 pandemic: health care disturbances and telemedicine as an alternative rheumatology practice in Indonesia","volume":"23","author":"Parlindungan","year":"2023","journal-title":"BMC Health Serv Res"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:55:11Z","timestamp":1757969711000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/lupus-2024-001336"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001336","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}